HUM vs RNA · P/E 39, rev $129.66B vs rev $10.9M
Humana Inc (HUM) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported HUM revenue for 2025-12-31 was $129.66B. Net income was $1.19B. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported RNA revenue for 2024-12-31 was $10.9M. Net income was -$322.3M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. RNA currently screens at market cap $217.5M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. RNA currently screens at market cap $217.5M.
Not investment advice. Open the HUM and RNA stock pages for the full models.
Not investment advice.